This article was originally published Feb. 6.

Following the burst of next-generation sequencing technologies onto the scene, Sanger sequencing may have slipped out of the limelight, but it is still laboring away in a few laboratories.

Robert Lyons, the director of the University of Michigan DNA Sequencing Core, said that while he has seen a decline in demand for Sanger sequencing, it has not been large. "The business has gone down about 10 percent," he said. "We still do 300,000 samples or 300,000 reactions a year here."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.